Fig. 4

Maximum intensity projection images of [¹⁸F]FDG PET on the baseline (a), after the first cycle of neoadjuvant chemotherapy (b), and after the second cycles of neoadjuvant chemotherapy (c) of a 12-year-old female with osteosarcoma of the right femur. After neoadjuvant chemotherapy, SUV_max has reduced by 67.9% and 67.0% after 1 cycle and 2 cycles of neoadjuvant chemotherapy, respectively. Although the patient showed a poor histologic response to neoadjuvant chemotherapy, the patient is alive without recurrence for 112 months after surgery